Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2010

Content (34 Articles)

Preclinical study

Breast cancer expresses functional NMDA receptors

William G. North, Guohong Gao, Vincent A. Memoli, Roy H. Pang, Launa Lynch

Preclinical study

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer

Karin Rennstam, Nicole McMichael, Pontus Berglund, Gabriella Honeth, Cecilia Hegardt, Lisa Rydén, Lena Luts, Pär-Ola Bendahl, Ingrid Hedenfalk

Preclinical study

Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer

Michael S. Sabel, Gang Su, Kent A. Griffith, Alfred E. Chang

Preclinical study

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

Lyndsay M. Murrow, Sireesha V. Garimella, Tamara L. Jones, Natasha J. Caplen, Stanley Lipkowitz

Preclinical study

Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody

H. J. Hnatyszyn, M. Liu, A. Hilger, L. Herbert, C. R. Gomez-Fernandez, M. Jorda, D. Thomas, J. M. Rae, D. El-Ashry, M. E. Lippman

Preclinical study

A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions

Matthew H. Herynk, Torsten Hopp, Yukun Cui, Airu Niu, Arnoldo Corona-Rodriguez, Suzanne A. W. Fuqua

Preclinical study

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance

Hitomi Imachi, Koji Murao, Hiroaki Dobashi, Mohammad M. Bhuyan, Xueyuan Cao, Keiichi Kontani, Shoko Niki, Chisa Murazawa, Hiroo Nakajima, Norio Kohno, Hiroko Yamashita, Hirotaka Iwase, Shin-ichi Hayashi, Toshihiko Ishida, Akira Yamauchi

Clinical trial

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Gabriel N. Hortobagyi, Henry L. Gomez, Rubi K. Li, Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Guillermo L. Lerzo, Xavier B. Pivot, Fernando Hurtado de Mendoza, Binghe Xu, Linda T. Vahdat, Ronald A. Peck, Pralay Mukhopadhyay, Henri H. Roché

Clinical trial

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

Vicky S. Sabine, Andrew H. Sims, E. Jane Macaskill, Lorna Renshaw, Jeremy S. Thomas, J. Michael Dixon, John M. S. Bartlett

Clinical trial

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

Jean-Yves Pierga, Suzette Delaloge, Marc Espié, Etienne Brain, Brigitte Sigal-Zafrani, Marie-Christine Mathieu, Philippe Bertheau, Jean Marc Guinebretière, Marc Spielmann, Alexia Savignoni, Michel Marty

Clinical trial

Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: a comparison of 99mTc-tin colloid and 99mTc-phytate efficiency

Ju Won Seok, Yoo Shin Choi, SeMin Chong, Gui Young Kwon, Yun Jae Chung, Beom Gyu Kim, Sung Jun Park

Epidemiology

Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis

Theodoros N. Sergentanis, Konstantinos P. Economopoulos

Epidemiology

XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis

Li-Xin Qiu, Chen Mao, Lei Yao, Ke-Da Yu, Ping Zhan, Bo Chen, Hai-Guang Liu, Hui Yuan, Jian Zhang, Kai Xue, Xi-Chun Hu

Epidemiology

Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls

Xiangyu Ma, Xiaowei Qi, Chunhai Chen, Hui Lin, Hongyan Xiong, Yafei Li, Jun Jiang

Epidemiology

No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: a meta-analysis based on 9,710 cases and 11,041 controls

Xiangyu Ma, Chunhai Chen, Hongyan Xiong, Jin Fan, Yafei Li, Hui Lin, Rufu Xu, Guorong Huang, Bin Xu

Epidemiology

Breast cancer survival in women of African descent living in the US and in the Caribbean: effect of place of birth

Emanuela Taioli, Allison Attong-Rogers, Penelope Layne, Veronica Roach, Camille Ragin

Epidemiology

Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects

Li-Xin Qiu, Lei Yao, Chen Mao, Ke-Da Yu, Ping Zhan, Bo Chen, Hui Yuan, Jian Zhang, Kai Xue, Xi-Chun Hu

Epidemiology

Temporal trends in area socioeconomic disparities in breast-cancer incidence and mortality, 1988–2005

Mario Schootman, Min Lian, Anjali D. Deshpande, Elizabeth A. Baker, Sandi L. Pruitt, Rebecca Aft, Donna B. Jeffe

Epidemiology

Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Konstantinos P. Economopoulos, Theodoros N. Sergentanis

Epidemiology

Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer

Jenny Chia-Yun Wu, Matti Hakama, Ahti Anttila, Amy Ming-Fang Yen, Nea Malila, Tytti Sarkeala, Anssi Auvinen, Sherry Yueh-Hsia Chiu, Hsiu-Hsi Chen

Brief Report

Two founder BRCA2 mutations predispose to breast cancer in young women

Mar Infante, Mercedes Durán, Adriana Lasa, Alberto Acedo, Miguel de la Hoya, Eva Esteban-Cardeñosa, David J. Sanz, Lucia Pérez-Cabornero, Enrique Lastra, Cristina Miner, Eladio A. Velasco

Brief Report

Evaluation of screening instruments for depression and anxiety in breast cancer survivors

Susanna Alexander, Clare Palmer, Patrick C. Stone

Brief Report

Orally administered Endoxifen is a new therapeutic agent for breast cancer

Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad

Brief Report

Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy

Anne H. Blaes, Philippe Gaillard, Bruce A. Peterson, Douglas Yee, Beth Virnig

Brief Report

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

Javier Puente, Sara López-Tarruella, Amparo Ruiz, Ana Lluch, Miguel Pastor, Emilio Alba, Juan de la Haba, Manuel Ramos, Luis Cirera, Antonio Antón, Antoni Llombart, Arrate Plazaola, Antonio Fernández-Aramburo, Javier Sastre, Eduardo Díaz-Rubio, Miguel Martin

Letter to the Editor

Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence

Miguel Muñoz, Marisa Rosso, Fernando Casinello, Rafael Coveñas

Letter to the Editor

High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients

Ava Kwong, E. K. O. Ng, F. B. F. Law, L. P. Wong, M. Y. To, M. T. Cheung, H. N. Wong, V. W. Chan, Allison Kurian, D. W. West, J. M. Ford, E. S. K. Ma

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine